Eurofins CDMO Europe in the news

Eurofins CDMO Alphora expanded its laboratory and high-potency active pharmaceutical ingredient capabilities to support increased demand for drug development and manufacturing.

Eurofins Scientific SE's stock performance is strong, with its CDMO unit expanding high-potency API capabilities in Canada.

Eurofins Scientific expanded its CDMO Alphora unit's capacity for high potency API development, leading to an 18.83% share price increase over three months, with the company currently assessed as 2.9% undervalued despite concerns about acquisition integration and cash flow from heavy investments.

Eurofins CDMO Alphora expanded its high-potency API development and manufacturing capacities in Canada to strengthen its CDMO offerings in North America, leading to a slight increase in Eurofins stock.

Eurofins CDMO Alphora expanded its kilolab and high-potency development and manufacturing capabilities to support complex drug development.

Eurofins CDMO Alphora expanded its Mississauga kilolab and high-potency development and manufacturing capabilities to support increased demand for complex and potent molecules.

Eurofins Scientific reported strong profit and cash flow growth in H1 2026, driven by margin expansion and strategic portfolio changes, despite modest organic revenue growth and challenges in the BioPharma segment.

Eurofins Scientific's Q2 earnings exceeded profit forecasts, but its shares declined due to modest organic growth and ongoing tech overhaul disruptions, despite strong margin expansion and free cash flow.

The global small molecule innovator API CDMO market is anticipated to grow significantly, driven by increased demand for small molecule drugs, outsourcing trends, and a surge in clinical trials.

Eurofins Scientific's shares tumbled after missing first-quarter organic growth forecasts, particularly in its biopharma division, despite maintaining full-year guidance.

Eurofins Scientific experienced a sharp stock decline following a first-quarter revenue miss caused by a slowdown in biopharma and adverse weather conditions.

Eurofins CDMO India appointed Dr. Kirithivasan Venkatesan as Senior Director Process R&D to enhance its drug development and manufacturing capabilities.

Eurofins CDMO Alphora is integrating advanced Continuous Flow technology into its API manufacturing operations, enhancing efficiency and supporting innovative pharmaceutical programs.

Eurofins CDMO Alphora integrates advanced Continuous Flow technology into its API manufacturing, enhancing process control, safety, and production agility with support from NRC IRAP.

Eurofins CDMO Alphora is integrating advanced Continuous Flow technology to enhance its Active Pharmaceutical Ingredient manufacturing capabilities and efficiency.

Eurofins CDMO Alphora integrated advanced Continuous Flow technology for API manufacturing, enhancing process control, safety, and production agility, with support from NRC IRAP.

Eurofins CDMO Alphora integrated advanced Continuous Flow technology into its API manufacturing capabilities, supported by NRC IRAP funding.

Polyrizon completed GMP manufacturing of clinical trial material for its intranasal drug candidate with Eurofins CDMO support.

Polyrizon completed GMP manufacturing of clinical trial material with Eurofins CDMO AmatsiAquitaine to support its planned U.S. clinical study of an intranasal hydrogel product.

Polyrizon successfully manufactured a GMP batch of clinical trial material for its lead product candidate with Eurofins CDMO AmatsiAquitaine S.A.S., supporting a planned U.S. clinical study.